VBL Therapeutics (VBLT) – Press Releases
-
Notable Labs Closes Merger Transaction With VBL Therapeutics
-
VBL Therapeutics Announces Results of Annual and Special Shareholder Meeting
-
VBL Therapeutics Reminds Shareholders to Vote in the Upcoming Annual and Special Shareholder Meeting
-
VBL Therapeutics Announces that S-4 Registration Statement for Proposed Merger with Notable Labs Is Declared Effective by SEC
-
VBL Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
-
VBL Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
-
VBL Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update
-
VBL Therapeutics Announces Closing of Sale of Manufacturing Facility and Certain Related Assets for $7.1 Million in Cash
-
Aleph Farms Increases Production Capabilities with VBL Therapeutics Facility Acquisition and ESCO Aster Partnership
-
VBL Therapeutics and Notable Labs Announce Definitive Merger Agreement
-
VBL Therapeutics Announces Agreement to Sell Manufacturing Facility and Certain Related Assets for $7.1 Million in Cash
-
VBL Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
-
VBL Therapeutics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
-
VBL Therapeutics Announces Second Quarter 2022 Financial Results and Corporate Process to Explore Strategic Options
-
VBL Therapeutics Announces Workforce Reduction
-
VBL Therapeutics Announces Top-Line Data from Phase 3 OVAL Trial of Ofra-Vec in Patients with Platinum-Resistant Ovarian Cancer
-
VBL Therapeutics to Participate in the Jefferies Healthcare Conference
-
VBL Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
-
VBL Therapeutics to Report First Quarter 2022 Financial Results on May 17
-
VBL Therapeutics to Participate in Upcoming Scientific and Industry Conferences in May
-
VBL Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
VBL Therapeutics Receives FDA Fast Track Designation for Ofra-Vec for the Treatment of Platinum-Resistant Ovarian Cancer
-
VBL Therapeutics to Host In-Person Key Opinion Leader Seminar on Ovarian Cancer
-
VBL Therapeutics Reports Full Year 2021 Financial Results and Provides Corporate Update
-
Alpha Tau Medical Ltd. Appoints Ruth Alon to its Board of Directors
-
UPDATE -- VBL Therapeutics to Report Year-End 2021 Financial Results on March 23
-
VLB Therapeutics to Report Year-End 2021 Financial Results on March 23
-
VBL Therapeutics Announces Completion of Enrollment in OVAL Phase 3 Registration-Enabling Trial of Ofra-Vec in Ovarian Cancer and Unanimous Recommendation by Independent Data Safety Monitoring Committ
-
VBL Therapeutics to Participate at March Investor Conferences
-
VBL Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
VBL Therapeutics to Participate in the Guggenheim Oncology Conference and the 2022 BIO CEO & Investor Conference
-
VBL Therapeutics Announces Appointment of Matthew Trudeau as Chief Commercial Officer
-
VBL Therapeutics to Present at H.C. Wainwright BioConnect Virtual Conference
-
VBL Therapeutics Selected for €17.5 Million of Funding from Horizon Europe EIC Accelerator Program
-
VBL Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update
-
VBL Therapeutics to Report Third Quarter Financial Results on November 15
-
VBL Therapeutics Announces Appointment of Sam Backenroth as Chief Financial Officer and Establishes Operations in the United States
-
VBL Therapeutics Announces Independent Data Safety Monitoring Committee Provides Clearance to Continue the OVAL Phase 3 Registration-Enabling Study of VB-111 in Ovarian Cancer
-
VBL Therapeutics to Present at Upcoming Conferences
-
VBL Therapeutics Resumes U.S. Enrollment in OVAL Phase 3 Trial as FDA Authorizes Clinical Use of VB-111 Batches Produced in Modiin Facility
-
VBL Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update
-
VBL Therapeutics to Report Second Quarter Financial Results on August 16
-
VBL Therapeutics Appoints Marc Kozin as Chairman of its Board of Directors
-
VBL Therapeutics Appoints Alison Finger and Michael Rice to its Board of Directors
-
VBL Therapeutics Provides Update on OVAL, a Phase 3 Registration Enabling Study of VB-111 in Ovarian Cancer
-
VBL Therapeutics Announces Addition of Progression Free Survival as a Second Primary Endpoint in OVAL, a Phase 3 Registration Enabling Study of VB-111 in Ovarian Cancer
-
VBL Therapeutics to Provide an Update on the OVAL Phase 3 Registration Enabling Study of VB-111 in Ovarian Cancer at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
-
VBL Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update
-
VBL Therapeutics to Report First Quarter Financial Results on May 11
-
Vascular Biogenics Ltd. Closes Public Offering of Ordinary Shares and Pre-Funded Warrants
Back to VBLT Stock Lookup
